Dent病高钙尿症和蛋白尿药物治疗的临床观察

摘要
图/表
参考文献
相关文章 (0)

全文: PDF (715 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要目的观察氢氯噻嗪联合枸橼酸钾、洛汀新分别对Dent病高钙尿症、蛋白尿的治疗效果。方法 2014年1月—2015年12月于北京大学第一医院收治Dent病患儿8例,明确诊断后给予氢氯噻嗪联合枸橼酸钾治疗,其中6例同时给予洛汀新治疗,监测患儿尿钙/肌酐、24 h尿钙、尿蛋白/肌酐、肾早期损伤、尿蛋白电泳、尿蛋白定量、肾脏钙化动态变化,以及肾功能、电解质的变化情况。结果 8例患儿经氢氯噻嗪联合枸橼酸钾治疗后,尿钙/肌酐和24 h尿钙均明显下降(P<0.001),治疗前后差异有统计学意义,其中6例(75%)恢复正常,随访最长18个月,无明显低钾血症,肾脏B超未见钙化。其中6例接受洛汀新治疗的患儿,治疗3~6个月后尿蛋白定量无明显变化(P>0.05)。结论氢氯噻嗪联合枸橼酸钾治疗Dent病,可以有效控制高钙尿症,而洛汀新对于Dent病的蛋白尿则无治疗效果。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	苏成选
	张宏文
	王芳
	刘晓宇
	肖慧捷
	姚勇

关键词 ： Dent病, 氢氯噻嗪, 枸橼酸钾, 洛汀新

Abstract：Objective To observe the treatment effects of dihydrochlorothiazide and lotensin on hypercalciuria and proteinuria in Dent disease. Methods Dihydrochlorothiazide and potassium citrate were given to 8 cases of Dent disease following the diagnosis; lotensin was giver to 6 of the 8 cases. The ratio of urinary calcium to creatinine, quantitative test of 24h urinary calcium and protein, early injury index of kidney, urine protein electrophoresis, renal function, and electrolytes were monitored.Results The ratio of urinary calcium to creatinine and urinary calcium quantity decreased significantly after the treatment (P<0.001), and returned to normal in 6 cases (75%), with a follow-up period of 18 months. No change in urinary protein was observed in the 6 cases treated with lotensin for 3 to 6 months (P>0.05).Conclusion Dihydrochlorothiazide and potassium citrate could effectively control hypercalciuria while lotensin showed no treatment effects on the proteinuria in Dent disease.

Key words： Dent’s disease Dihydrochlorothiazide Potassium Citrate Lotensin

收稿日期: 2016-04-05

通讯作者: 张宏文(zhanghongwen@126.com)

引用本文:

苏成选, 张宏文, 王芳, 刘晓宇, 肖慧捷, 姚勇. Dent病高钙尿症和蛋白尿药物治疗的临床观察[J]. 中国生育健康杂志, 2016, 27(4): 324-327.
SU Chengxuan, ZHANG Hongwen, WANG Fang, LIU Xiaoyu, XIAO Huijie, YAO Yong. Treatment of Dent disease with dihydrochlorothiazide and lotensin:an analysis of 8 cases. Chinese Journal of Reproductive Health, 2016, 27(4): 324-327.

链接本文:

http://cjrh.bjmu.edu.cn/CN/ 或 http://cjrh.bjmu.edu.cn/CN/Y2016/V27/I4/324

1 Devuyst O.Dent’s disease:chloride-proton exchange controls proximal tubule endocytosis.Nephrol Dial Transplant,2010,25:3832-3835.
2 Cho HY,Lee BH,Choi HJ,et al.Renal manifestations of Dent disease and Lowe syndrome.Pediatr Nephrol,2008,23:243-249.
3 Annigeri RA,Rajagopalan R:Hypophosphatemic rickets due to Dent’s disease:A case report and review of literature.Indian J Nephrol,2009,19:163-166.
4 Grand T,L’Hoste S,Mordasini D,et al.Heterogeneity in the processing of CLCN5 mutants related to Dent disease.Hum Mutat,2011,32:476-483.
5 Hoopes RR,Raja KM,Koich A,et al.Evidence for genetic heterogeneity in Dent’s disease.Kidney Int,2004,65:1615-1620.
6 朱碧溱,李鹏,黄建萍.以小分子蛋白尿为主要表现的六例Dent 病临床及基因分析.中华儿科杂志,2010,48:329-333.
7 Grand T,Mordasini D,L’Hoste S,et al.Novel CLCN5 mutations in patients with Dent’s disease result in altered ion currents or impaired exchanger processing.Kidney Int,2009,76:999-1005.
8 Hoopes RR,Shrimpton AE,Knohl SJ,et al.Dent Disease with mutations in OCRL1.Am J Hum Genet,2005,76:260-267.
9 李鹏,黄建萍.小儿Dent病临床特征和基因突变分析.临床儿科杂志,2008,26:298-301.
10 Addis M,Meloni C,Tosetto E,et al.An atypical Dent’s disease phenotype caused by co-inheritance of mutations at CLCN5 and OCRL genes.Eur J Hum Genet,2013,21:687-690.
11 Vaisbich MH,Henriques Ldos S,Igarashi T,et al.The long-term use of enalapril and hydrochlorothiazide in two novel mutations patients with Dent’s disease type 1.J Bras Nefrol,2012,34:78-81.
12 Raja KA,Schurman S,D’Mello RG,et al.Responsiveness of hypercalciuria to thiazide in Dent’s disease.J Am Soc Nephrol,2002,13:2938-2944.
13 Blanchard A,Vargas-Poussou R,Peyrard S,et al.Effect of hydrochlorothiazide on urinary calcium excretion in dent disease:an uncontrolled trial.Am J Kidney Dis,2008,52:1084-1095.
14 Szczepanska M,Zaniew M,Recker F,et al.Dent disease in children:diagnostic and therapeutic considerations.Clin Nephrol,2015,84:222-230.